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Administration of Long-Acting Injections
Abstract
Expanding the scope of pharmacy practice demonstrates that the profession has been successful at
improving public health. Despite being a late adopter, New York's limited experience with vaccines has
improved immunization rates and lowered rates of disease. During emergencies, the 2017-2018 flu
season for example, the state has turned to pharmacists to go beyond what the pharmacy practice law
permits, in this case enabling immunizations in pediatric patients.1 This illustrates recognition of
untapped potential within the profession to contribute to the public health. Another opportunity for
pharmacists to enhance the public health is embodied in a Bill introduced in the New York State
Legislature that would amend the pharmacy practice law to enable administration of "long-acting
injectables" designed to treat mental health disorders including schizophrenia and substance use
disorder ("SUD"). The goal of this paper is to review the proposed amendment, the relevant background,
and to discuss the implications for patients and the pharmacy profession.
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Administration of Long-Acting Injections
Christopher Noel, PharmD BCPP, Wegmans School of Pharmacy, and
Karl Williams, RPh, LLM, JD, Wegmans School of Pharmacy
Expanding the scope of pharmacy practice demonstrates that the profession has been successful at improving public health. Despite being a late adopter, New
York's limited experience with vaccines has improved immunization rates and lowered rates of disease. During
emergencies, the 2017-2018 flu season for example, the
state has turned to pharmacists to go beyond what the
pharmacy practice law permits, in this case enabling immunizations in pediatric patients.' This illustrates recognition of untapped potential within the profession to con tribute to the public health. Another opportunity for pharmacists to enhance the public health is embodied in a Bill
introduced in the New York State Legislature that would
amend the pharmacy practice law to enable administration of ·1ong-acting injectables· designed to treat mental
health disorders including schizophrenia and substance
use disorder ("SUD'). The goal of this paper is to review
the proposed amendment, the relevant background, and
to discuss the implications for patients and the pharmacy
profession.

tal health and substance use disorder, as prescribed or
ordered by a licensed prescriber in this state and in accordance with regulations promulgated by the commissioner in consultation with the board of pharmacy."

The Legislation

Patients and doctors have a wide variety of attitudes
regarding the use of LAI antipsychotics. There is a more
negative attitude held by treating clinicians, especially in
those recently diagnosed with schizophrenia versus more
chronic patients. A European study determined that, of
nearly 900 healthcare professionals (physicians and nurses) surveyed, 40% preferred LAls in first-episode psychosis
(FEP) where 90% would prefer them in patients who have
had two to five psychotic episodes.4 Patients may have
negative attitudes about LAls as well, but this may be due
to a lack of information coming from their provider. In
one study, when an LAI was offered to an LAI-naive patient, more often the response was neutral or favorable
(63%) versus unfavorable (37%).' Multiple studies have
confirmed that attitudes toward LAI antipsychotics is majorly dependent on previous exposure-many patients
who have tried LAls prefer this treatment over oral medications as they •feel better•, have a more ·normal life• and
find the injections ·easier to remember".2 Other advantages that LAls have over oral medications that are
supported by the literature are the lack of need for daily
administration, transparency of adherence, a lower likelihood of relapse rates and rebound symptoms, reduced
peak-trough plasma levels, and improved patient satisfaction and outcomes.?

Assembly Bill A08661, sponsored by Assemblyman
John McDonald, explains the thinking behind this proposal
in its •Justification" section. New York is among a minority
of states (eleven) that does not permit pharmacists to administer ·non-vaccine items· such as long-acting injections ('LAls") for mental health disorders. Lack of adherence to oral forms of medication is one of the key reasons
cited for this legislation. Inability, or unwillingness, to take
medication as prescribed results in clinical relapse, patient
suffering, and high rates of readmission to facilities for
inpatient care. Non-adherent patients are five-times more
likely to require additional inpatient care than adherent
patients. The justification further explains that community
pharmacies are ideal partners in the care of these patients
because the better proximity to, and accessibility by patients. Perhaps less intuitive, but more important, there is
a stigma associated with reporting to a mental health clinic periodically for medication. No such stigma attaches to
community pharmacies.
The Bill amends Article 137 of the Education Law relating to the practice of pharmacy by expanding those medications that pharmacists may provide under the definition
of •Administer•. Currently limited to a very short list of
vaccines, the proposal creates a new subsection (6802(22)
(b)) that includes: ·medications for the treatment of men-
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In addition, the Bill would add a new subdivision, six,
to the 'Definition of pharmacy practice·. Section 6801(6)
explicitly states that a •licensed pharmacist may administer
injectable medications for mental health and substance
use disorder:
Schizophrenia
Schizophrenia is a serious and disabling mental illness
that affects 1.1% of the US population. 2 The first antipsychotic medication was introduced in the 1950s; shortly
thereafter, it was clear that adherence to these medications was a major issue. In the mid-late 1960s, the first
long-acting injectable (LAI) antipsychotic was introduced--however, buy-in was not universal as some were
skeptical of increased side effects, lack of efficacy, and
questions of the ethics of this dosage formulation.3

LAls have gained favor in the eyes of clinicians and
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patients. These are now starting to be recommended for
those experiencing first-episode schizophrenia (FES) and
are regularly recommended for those with chronic multiepisode schizophrenia or adherence issues (Table 1).
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Substance Use Disorder
Substance use disorder, opioids in particular, continues
to be one of the most vexing diseases, resulting, since
1999, in escalating morbidity and mortality. Despite broad
recognition, the epidemic continues to advance. In November 2017, the Centers for Disease Control reported that
nationwide data for the period October 2015 through October 2016 showed fatal overdoses continued to increase,
killing over 42,000 people - a five-fold increase over 1999,
and netting out to more than 600,000 people. 6 Chillingly,
this represents 115 deaths each day.
Medications available to treat opioid use disorder are
methadone, buprenorphine, and naltrexone - all of which
come in various dosage formulations with only certain formulations proving to be more efficacious than placebo in
controlled studies. Methadone, the most widely studied
and used medication for opioid use disorder, comes in
tablet and liquid formulations; it has been shown to reduce
illicit opioid use, treat opioid use disorder, and retain patients in treatment better than placebo or no medication.7
Two medications available as a LAI and focused on herein
are extended-release (monthly) subcutaneous injectable
buprenorphine and extended-release (every 4 weeks) intramuscular naltrexone.
Buprenorphine retains patients in treatment and reduces illicit opioid use better than placebo. 6 Compared to
methadone's full mu-agonist properties, it is a partial agonist with a ceiling effect, which makes it less likely to cause
respiratory depression and safer in overdose (although not
free of risk in overdose situations). The monthly subcutaneous injectable formulation of buprenorphine is FDAapproved for moderate to severe opioid use disorder in
patients who are started on transmucosal buprenorphine
for at least 7 days. The medication is injected into the subcutaneous tissue of the abdomen of the patient at a dose
of 300 mg for the first two months, and then 100 mg
monthly thereafter. Extended-release naltrexone is more
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effective than placebo in reducing risk of return to opioid
use and is proven to be non-inferior to daily buprenorphine in terms of treatment retention and reduction of illicit
opioid use in a 12-week Norwegian trial (n=159). It is FDA-

approved to prevent return to opioid dependence following medically supervised opioid withdrawal. The medication is injected into the muscle of the upper outer quadrant
of the gluteal area at a dose of 380 mg every 4 weeks. Interestingly, a Cochrane review (13 trials, n=l, 158) concluded
that oral naltrexone was not superior to placebo in treatment retention or illicit opioid use reduction.
In December 2016, the National Alliance of State Pharmacy Associations (NASPA) and the College of Psychiatric
and Neurologic Pharmacists (CPNP) gathered to specifically discuss pharmacist administration of LAls.8 In addition to
these and other pharmacy organization representatives,
there were representatives from the American Psychiatric
Association, the Department of Defense, the Substance
Abuse and Mental Health Service Administration, the National Alliance on Mental Illness, and the United States
Public Health Service, among others.9 The unmet need to
provide patients increased access to these medications was
addressed. When it comes to those diagnosed with schizophrenia, about half are not taking their medications as prescribed. For this reason, LAls have gained favor but certain
barriers remain including scheduling challenges, limited
personnel and inventory in clinics, reimbursement issues,
and lack of transportation for the patient to and from the
clinic. The conclusions of the stakeholder meeting were
that 1) pharmacists can play a vital role in the effort to improve patient access to these medications and 2) states
that do not currently have legislation for pharmacist administration of LAls should consider incorporating new policies.
Discussion
This amendment to the pharmacy practice law comes
at a time that the pharmacy profession here in New York is
well-positioned to help address the medication adherencerelated public health issues identified in the Bill. Viewed as
a public health resource, the profession has developed the
'infrastructure' to fulfill the goals of the A08661. In 2008 the
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scope of practice expanded to permit pharmacists to administer a short list of vaccines. In response, pharmacy
schools, the profession, and the Board of Pharmacy mobilized to provide additional education and training necessary to administer these injectable products safely and effectively. As a result, the framework is in place to include
additional medications and disease states envisioned in the
Bill. Training would include medication-specific information,
the patient-specific counseling, and other aspects of care.
These are now cornerstones of our profession.
Assembly Bill A08661 will only narrowly expand the list
of those medications that trained pharmacists can administer. While it is intuitive that A08661 will improve the public
health as intended in connection with schizophrenia, it
could go further.
Thirty-nine states permit pharmacists to administer any
medication. For example, in Kentucky the ' Practice of Pharmacy'
includes
sweeping
language
permitting
"administration of medications or biologics in the course of
dispensing or maintaining a prescription drug order:t0 Al so, seven states currently permit pharmacists to prescribe
controlled substances.11 The Drug Enforcement Administration characterizes pharmacists in these states as 'mid-level
practitioners'. With help from Congress and New York
State pharmacists could work collaboratively with other
heallh professions, prescribing buprenorphine under protocol permitting profoundly greater access to necessary care.
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(ED artide continued from page 5)
New Legislation
PSSNY has developed bill language very similar to
the Governor's budget proposal last year that would
register and license PBMs. We are in conversations with
Assembly member Gottfried and Senator Hannon to
negotiate language acceptable to both houses and to
identify bill sponsors. Once the budget passes, this will
be PSSNY's top priority.
Influence of Media Coverage
PSSNY has retained a consultant to build a media
presence that has helped us get to where we are today.
We are continuing the effort to increase awareness of
PBM practices, the role of the pharmacist on the
healthcare team and the impact both have on the care
of the patient.
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Some of the more powerful pieces include:
States Fight Back Against Unfair Prescription
Pricing Pradires, (WNYT.com, March 5, 2018)
Regulators Push to End Prescription Gag
Clauses, (NBC News NY, February 27, 2018)
Why Your Pharmacist Can't Tell You That $20
Prescription Could Cost Only $8, (New York
Times - February 25, 2018)

To see the most recent coverage, please visit:
PSSNY's Press Room: www.PSSNY.org/PressRoom.
Please watch the website and your email inbox for
breaking news on our legislative activities. Information
can change quickly and often. The information in this
article was accurate at the time the Journal went to press.
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